Therapies developed for adult patients with heart failure have been shown to be ineffective in pediatric clinical trials, leading to the recognition that new pediatric-specific therapies for heart failure must be developed. Administration of the recombinant growth factor neuregulin-1 (rNRG1) stimulates regeneration of heart muscle cells (cardiomyocytes) in adult mice. Because proliferation-competent cardiomyocytes are more abundant in growing mammals, we hypothesized that administration of rNRG1 during the neonatal period might be more effective than in adulthood. If so, neonatal rNRG1 delivery could be a new therapeutic strategy for treating heart failure in pediatric patients. To evaluate the effectiveness of rNRG1 administration in cardiac regeneration, newborn mice were subjected to cryoinjury, which induced myocardial dysfunction and scar formation and decreased cardiomyocyte cell cycle activity. Early administration of rNRG1 to mice from birth to 34 days of age improved myocardial function and reduced the prevalence of transmural scars. In contrast, administration of rNRG1 from 4 to 34 days of age only transiently improved myocardial function. The mechanisms of early administration involved cardiomyocyte protection (38%) and proliferation (62%). We also assessed the ability of rNRG1 to stimulate cardiomyocyte proliferation in intact cultured myocardium from pediatric patients. rNRG1 induced cardiomyocyte proliferation in myocardium from infants with heart disease who were less than 6 months of age. Our results identify an effective time period within which to execute rNRG1 clinical trials in pediatric patients for the stimulation of cardiomyocyte regeneration.
INTRODUCTION
Congenital heart disease (CHD) is the leading cause of birth defectrelated morbidity and mortality (1, 2) . Although corrective surgery enables young patients to survive most forms of CHD, they are at risk of developing chronic heart failure (3). The currently available therapies for heart failure-such as b-blockers and angiotensin-converting enzyme inhibitors-were developed for adult patients, but subsequently were shown to be ineffective in controlled pediatric trials (4) (5) (6) . There is an increasing awareness that the underlying mechanisms of heart failure are different in pediatric patients than in adults, and thus new therapeutic paradigms must be developed (4) .
The goal of cardiac regeneration is to provide new functionally integrated heart muscle cells (cardiomyocytes). Three principal strategies are being pursued: transplantation of stem cells, transdifferentiation of fibroblasts into cardiomyocytes, and stimulation of endogenous cardiomyocyte proliferation (7, 8) . Although human adults show little or no endogenous cardiomyocyte proliferation, this does not seem to be true for younger people under 20 years of age (9, 10) . In fact, cardiomyocyte proliferation contributes to physiological heart growth in young humans (10) . Cardiomyocyte proliferation during postnatal heart growth was also shown in mouse and rat pups, but proliferation declines significantly during the first week of life (11, 12) . The rate of endogenous cardiomyocyte proliferation is higher in neonatal mice (1 to 4 days after birth) than in preadolescent mice (14 to 18 days after birth) and adult mice (60 days after birth) (11, 13, 14) . Neonatal mice were reported to be capable of scarless regeneration (15) (16) (17) , in contrast to preadolescent mice, which can only partially regenerate after myocardial injury (14) . Although endogenous cardiomyocyte proliferation can be detected in humans without heart disease up to 20 years of age (10) , the presence of heart disease likely influences the rate of cardiomyocyte proliferation.
Neuregulin-1 (NRG1), a member of the epidermal growth factor family, is required for cardiac development (18, 19) and for limiting injury after myocardial ischemia (20) . Administration of recombinant NRG1 (rNRG1) preparations is beneficial in a variety of small and large animal models of acquired heart disease (21) (22) (23) (24) . rNRG1 is currently being pursued as an investigational new drug for the treatment of heart failure (25, 26) and has been shown to be effective in adult patients with a left ventricular ejection fraction (LVEF) <40% (27, 28) . Thus, rNRG1 is available and suitable for administration in humans.
Different mechanisms of action have been proposed to explain the beneficial effects of rNRG1 administration in heart failure (29, 30) . Because rNRG1 stimulates cardiomyocyte proliferation (22, 24, 29, 30) , it has the potential to benefit pediatric patients. Here, we combine heart regeneration experiments in neonatal mice with cell biological experiments in intact human myocardium to characterize the period of cardiomyocyte proliferation, the ability to stimulate proliferation with rNRG1, and the relationship between the timing of rNRG1 administration and myocardial repair.
RESULTS

Cryoinjury in neonatal mice induces myocardial cell death
We used cryoinjury to create a neonatal mouse model of myocardial dysfunction and scarring and emulated key elements of previously published amputation and cryoinjury methods used in zebrafish (31) (32) (33) (34) and in neonatal mice (35, 36) . We fashioned a metal cryoprobe, cooled it in liquid nitrogen for~20 min, and applied it to the surface of the heart for 2 s. Using this technique, we performed more than 500 surgeries on the first day of life (P1) and observed a 24-hour mortality of 20% and a mortality of 25% between 24 hours and 7 days post-injury (dpi). Mortality was largely associated with maternal cannibalism.
Having implemented a feasible and survivable injury technique, we examined the extent and degree of tissue injury achieved by cryoinjury. Bright-field microscopy showed superficial hemorrhages at 1 dpi (Fig. 1A) , and vital staining with triphenyltetrazolium chloride (TTC) demarcated the injured region on the surface of the heart (Fig. 1B) . The extent of myocardial death was visualized by terminal deoxynucleotidyl transferasemediated deoxyuridine triphosphate nick end labeling (TUNEL) staining on histological sections (Fig. 1C) . The TUNEL-positive myocardial volume at 1 dpi was 0.58 ± 0.02 mm 3 (n = 6), corresponding to~18% of the myocardium (Fig. 1D ). Staining with a sarcomeric marker revealed disorganized sarcomeres and an overall decreased abundance of sarcomeric proteins in the cryoinjured area ( fig. S2 ).
Cryoinjury induces myocardial dysfunction and scarring
We performed echocardiography to examine the degree and time course of myocardial dysfunction after cryoinjury on P1. The left ventricular ejection fraction (LVEF) decreased in the control hearts between 4 and 14 dpi (Fig. 1E) , consistent with the previously reported decrease in contractility within this age range (37) . Cryoinjury reduced the EF significantly at all time points examined. As an example, at 30 dpi, the EF in the cryoinjury group was 45.7 ± 3% (n = 19) compared to 57.9 ± 3.5% (n = 19; P < 0.05, ANOVA) in sham mice. Thus, cryoinjury induced significant and sustained myocardial dysfunction.
We also examined the extent and time course of myocardial injury and observed fibrin deposition at 1 dpi and significant fibrosis at 7 dpi, which matured into transmural scars (that is, the radial myocardial wall dimension is composed of scar) at 30 dpi (Fig. 1F and fig. S3 ). We followed a group of mice for 7 months after cryoinjury, and they all showed transmural scars (n = 6; Fig. 1G and fig. S4 ). Morphometric analysis revealed that the relative scar volume after neonatal cryoinjury was comparable to values obtained after ligation of the left anterior descending artery (LAD ligation) in adult mice, which means that the amount of scar produced after neonatal cryoinjury is equal to that produced after experimental myocardial infarction in adult mice (Fig.  1H) (22) . In summary, cryoinjury in neonatal mouse hearts on P1 induced persistent myocardial dysfunction and scar formation.
Cryoinjury reduces cardiomyocyte cycling
Our data demonstrated a lack of significant regeneration at the structural (scar, Fig. 1F ) and functional levels (echocardiography, Fig. 1E ) and raise the question of whether there is evidence of cardiac regeneration at the cellular level. Because cardiomyocyte cell cycle activity was shown to increase with myocardial regeneration in zebrafish (38) and neonatal mice (15, 16) , we evaluated this mechanism by visualizing cardiomyocytes in karyokinesis using an anti-phospho-histone H3 (H3P) antibody. In sham-operated and cryoinjured hearts, the overall number of H3P-positive cardiomyocytes decreased significantly between 1 and 7 dpi (Fig. 1, I and J), consistent with prior studies showing that cardiomyocyte cell cycle activity decreases in the first week of life (11, 12) . However, the numbers of H3P-positive cardiomyocytes in the injury and border zones were significantly lower in cryoinjured hearts at 1, 4, and 7 dpi compared with the corresponding region in sham-operated hearts (Fig. 1J) . These results indicate that cryoinjury in neonatal mice inhibits endogenous cardiomyocyte cell cycle activity and, thus, that neonatal hearts do not regenerate to the same degree after cryoinjury as reported for hearts after myocardial resection or LAD ligation (15, 17) .
Administration of rNRG1 improves myocardial function
Because administration of rNRG1 stimulates cardiomyocyte cycling and proliferation in vitro and myocardial repair in vivo (22, 24, 29, 30) , we investigated the effect of rNRG1 on cardiomyocyte cycling in our cryoinjury mouse model. Toward this goal, we performed two independent preclinical studies in which only the beginning of rNRG1 therapy was varied (schematic shown in Fig. 2A ). In both experiments, cryoinjury was induced 1 day after birth in all animals, with control animals receiving daily injections of bovine serum albumin (BSA) and test animals receiving daily injections of rNRG1 (100 ng/g). In the first study (referred to as "early administration" from here on), therapy began at birth and continued every day for 34 days. These mice showed a significant improvement in their EF (measured by echocardiography) beginning at 5 dpi (Fig. 2B) . The absolute improvement of the EF was increased by 14 dpi and persisted for 30 days (64 dpi) after cessation of rNRG1 administration. Cardiac magnetic resonance imaging (cMRI), performed by a blinded core laboratory at 64 dpi, showed an increase of the EF from 44.3 ± 2.7 (n = 6) in BSA-treated mice to 58.3 ± 1 (n = 5; P < 0.0001, Student's t test) in rNRG1-treated mice, in agreement with the echocardiography results (Fig. 2C, fig.  S5 , and movies S1 and S2). The relative heart weights were significantly lower in rNRG1-treated mice at 64 dpi (Fig. 2D ), indicating that rNRG1 administration induced beneficial changes in the myocardium that persisted for 30 days after cessation of therapy.
In the second study (referred to as "late administration" from here on), we began therapy at 5 days after birth (4 dpi) and kept the remainder of the experimental design the same. Echocardiography showed a significant increase in the EF, first observed at 14 dpi (Fig. 2E) . However, at 64 dpi (that is, 30 days after cessation of rNRG1 injections), echocardiography and cMRI showed that the EF was no longer different between BSA-and rNRG1-treated mice (Fig. 2, E and F, fig. S6 , and movies S3 and S4). There also were no significant changes in heart weight after late administration (Fig. 2G) . In summary, early administration of rNRG1 yielded sustained improvements in cardiac function, leading to the conclusion that the timing of rNRG1 therapy is important for long-term results.
Early administration of rNRG1 prevents transmural scar formation We examined histological sections for scar formation at 10, 34, and 64 dpi (Fig. 2H and figs. S7 and S8). Quantification of the scar size at 10 dpi showed a statistically significant decrease in rNRG1-treated mice after early administration but not after late administration (Fig. 2, I and J). The relative scar size at 64 dpi (that is, when mice reached adult age) was~2.5% after early and late administration (Fig. 2, I and J), which is comparable to our measurements in adult mice after LAD ligation (22) . At 34 and 64 dpi after early administration of rNRG1, only one heart showed a transmural scar (n = 10; Fig. 2K ).
In contrast, 76.5% of mice starting rNRG1 late (n = 12) or receiving BSA (n = 22) showed transmural scars at 34 and 64 dpi (P = 0.0003, Fisher's exact test on raw data; Fig. 2K ). In conclusion, early rNRG1 and analysis of variance (ANOVA) followed by Bonferroni's multiple comparison test (E, H, and J). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Cryo, cryoinjury. , and Fisher's exact test (K). *P< 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001; ns, not significant.
administration prevents transmural scar formation without affecting the total volume of scar tissue.
Nontransmural scars contract and contain cardiomyocytes with electromechanical connections
We examined the functionality of the myocardium in nontransmural scars by cMRI (Fig. 2L ). To this end, we measured the thickness of nontransmural scars in the relaxed (diastole) and contracted (systole) states and calculated relative myocardial thickening, a measurement of myocardial function (Fig. 2M ). The thickening of nontransmural injury sites was similar to the corresponding remote LV free wall myocardium (Fig.  2M ). In contrast, the thickness of transmural scars in the late rNRG1 and BSA groups was so low that it could not be measured, even after enhancement by gadolinium injection, which highlights scar tissue ( fig. S9 ).
We then examined the extent to which cardiomyocytes in nontransmural scars exhibited gap junctions, which are structures that provide electromechanical connections between adjacent cells. We visualized gap junctions with an antibody against connexin 43 (a key structural protein of gap junctions) ( Fig. 2N ) and found that transmural scars did not contain gap junctions (Fig. 2N , upper panels, and movie S5). In contrast, nontransmural scars had intact myocardium and gap junctions ( Fig. 2N , lower panels, and movie S5). These results show that early administration of rNRG1 induces the formation of functionally active myocardium.
Early administration of rNRG1 preserves myocardium
Because early administration of rNRG1 began before cryoinjury, we considered a cardioprotective effect. The size of the hematoma demarcating the contact site between the myocardium and the cryoprobe was similar in control and rNRG1-treated mice, indicating that the extent of initial injury was not affected by rNRG1 (Fig. 3, A and B) . However, at 1 dpi, mice treated with BSA had 0.88 ± 0.04 mm 3 (n = 6) TUNELpositive myocardium and rNRG1-treated mice had 0.51 ± 0.07 mm 3 (n = 5) TUNEL-positive myocardium, representing a significant decrease (P = 0.0009, Student's t test; Fig. 3 , C and D). The difference (that is, 0.37 mm 3 at 1 dpi) represents the myocardium protected by rNRG1 and corresponds to 13.6% of the heart. Assuming that~1 × 10 6 cardiomyocytes exist in the heart at birth (14) , rNRG1 rescues~136,000 cardiomyocytes at 1 dpi (Supplementary Results). This suggests that the first two rNRG1 injections of the early administration protocol elicited a small cardioprotective effect.
Administration of rNRG1 stimulates cardiomyocyte cell cycling
Because rNRG1 increases cardiomyocyte cell cycling in vitro (29, 30) and in vivo (22, 24) , we examined the effect of rNRG1 on the cell division cycle in the cryoinjured mouse neonates by quantifying the number of H3P-positive cardiomyocytes on histological sections (Fig. 3 , E to G). Early administration of rNRG1 induced a twofold increase in H3P-positive cardiomyocytes compared with BSA-injected animals at 1 and 10 dpi (Fig. 3F ). Late administration of rNRG1 showed a similar effect at 10 dpi (Fig. 3G) ; however, the increase in cardiomyocyte cycling started 5 days later relative to the animals that received rNRG1 early administration. We examined histological sections for evidence of cardiomyocyte mitosis at 1 dpi and found a significant increase in the number of Aurora B kinase-positive cells in rNRG1 early treated animals (Fig. 3, H and I ). These findings show that rNRG1 increases cardiomyocyte mitosis.
Early administration of rNRG1 stimulates significant cardiomyocyte regeneration in the first 10 days of life We used stereology to quantify cardiomyocyte nuclei on a-actinin-and Hoechst-stained sections. Early administration of rNRG1 induced an 18% increase in cardiomyocyte nuclei density compared to BSA-treated mice at 64 dpi (Fig. 3J) . We correlated these directly determined stereology results with the predicted number of regenerated cardiomyocytes using our cell cycle data (H3P) and a linear regression model. We then calculated the difference in cardiomyocyte volume density (in mm −3 ) between BSA-and rNRG1-treated mice for six age bins between birth and 34 days of age and plotted the rNRG1-induced increase for each bin ( Fig. 3K and Supplementary Results). Between 1 and 10 dpi, there was a steep slope for the rNRG1-induced increase in the number of cardiomyocytes (slope, 3661 cardiomyocytes/mm 3 per day; Fig. 3K ). In other words, rNRG1 treatment stimulated the generation of~36,610 additional cardiomyocytes/mm 3 during the first 10 days of life. This accounts for~78% of the total number of new cardiomyocytes generated during this period. After 10 days of life, the rate of rNRG1-stimulated cardiomyocyte proliferation declined significantly to~96 cardiomyocytes/mm 3 per day, resulting in 2,300 new cardiomyocytes/mm 3 generated between days 10 and 34. These calculations indicate that rNRG1-stimulated cardiomyocyte proliferation in mice was most active in the first 10 days of life (Fig. 3K) . In summary, both the timing of rNRG1 administration and the animal age [P0 (day of birth) to P5] are critical determinates of the ability to regenerate myocardium.
ErbB4 expression in cardiomyocytes is required for rNRG1-stimulated cardiomyocyte cell cycling We showed previously that adult cardiomyocytes require the receptor tyrosine kinase ErbB4 for rNRG1-stimulated cycling (22) . However, it is possible that, in neonatal hearts, rNRG1 also acts on stem or progenitor cells via ErbB4. To explore this possibility, we used ErbB4 floxed mice to inactivate the NRG1 receptor gene (ErbB4) in cardiomyocytes. We administered tamoxifen in aMHC-MerCreMer; ErbB4 F/WT mice (control group) and in aMHC-MerCreMer; ErbB4 F/F mice (test group) from P0 to P3, which led to a significant reduction in ErbB4 mRNA levels (Fig.  4A) . We then quantified H3P-positive cardiomyocytes at P12 and found that rNRG1 increased the number of H3P-positive cardiomyocytes in control mice (n = 3) but not in test mice (n = 3), indicating that ErbB4 is required for rNRG1-stimulated cardiomyocyte cell cycling (Fig. 4 , B and C). Collectively, these data indicate that rNRG1 acts directly on cardiomyocytes, rather than stem cells, via ErbB4 to induce the cell division cycle.
Cryoinjury and rNRG1 administration induce gene regulation patterns that are consistent with structural and functional changes We next investigated changes in gene expression profiles induced by cryoinjury and rNRG1 administration. To this end, we induced cryoinjury on P1 and performed RNA sequencing (RNAseq) after early administration of BSA (n = 5) or rNRG1 (n = 5). Compared with sham (n = 5), cryoinjury (n = 5) was correlated with a change in the expression of 2,867 genes. We examined a heat map of 622 genes that were regulated in a significantly different manner in the BSA-and rNRG1-treated groups relative to sham-operated mice (P < 0.05, Cuffdiff; Fig. 5A and table S1). Genes that were significantly up-regulated (P < 0.05) by rNRG1 treatment included cyclic adenosine monophosphate-dependent transcription factor 3 (ATF3), geminin (Gmnn), centromere protein A (Cenpa), growth differentiation factor 15 (GDF15), connective tissue growth factor (Ctgf), and apelin (Apln). In addition, gap junction protein g2 (Gjc2) was up-regulated in rNRG1-treated hearts, consistent with our finding that early administration of rNRG1 induced the formation of functional myocardium. Genes that were significantly down-regulated (P < 0.05) included collagen 23a1 (Col23a1), suppressor with an antibody against Aurora B kinase (H) and quantified around the injury zone after early administration at 1 dpi (I). (J) Cardiomyocyte nuclear density is increased after early administration of rNRG1 (34 dpi). (K) Early administration of rNRG1 increases the cardiomyocyte density by~62,000 cardiomyocytes/ mm 3 within the first 8 days, compared to BSA controls. CM, cardiomyocytes. Scale bars, 1 mm (A) and 20 mm (C, E, and H). Statistical significance was tested with Student' s t test (B, D, I, and J) and ANOVA followed by Bonferroni' s multiple comparison test (F and G). *P < 0.05, ***P < 0.001, ****P < 0.0001; ns, not significant.
of cytokine signaling 1 (SOCS1), bone morphogenic protein 10 (BMP-10), interleukin-6 (IL-6), and glycerophosphodiester phosphodiesterase domain-containing protein 3 (GDPD3). Functional annotation clustering revealed that the genes whose expression changed with rNRG1 treatment encoded cytokines, cell growth and division regulators, and transcription factors (Fig. 5B) . In summary, the broad changes in gene regulation paralleled the observed functional and structural changes.
Cardiomyocyte cell cycling is decreased in pediatric patients with heart disease The results from our mouse studies suggest that rNRG1 therapy is most effective during an early-administration therapeutic period. To determine whether a similar trend is present in humans, we examined myocardium obtained from patients with heart disease (for clinical characteristics, see tables S2 and S3). Although cardiomyocyte proliferation occurs in humans without heart disease up to 20 years of age, the presence of heart disease might influence cardiomyocyte cell cycle activity. We isolated cardiomyocytes from patient samples, stained them with antibodies against pan-cadherin to determine cell quality (Fig. 6A) , and then used flow cytometry to quantify the population of cardiomyocytes that were H3P-positive; H3P-positive cardiomyocytes were detected in patients younger than 6 months but not in patients older than 6 months (Fig. 6, B and C) . Furthermore, cardiomyocytes from patients with heart disease exhibited lower cell cycle activity compared to nondiseased myocardium (Fig. 6C) . Together, these findings suggest that pediatric patients with heart disease exhibit lower levels and earlier cessation of cardiomyocyte cell cycle activity relative to pediatric donor hearts without disease.
Infants with heart disease have the capacity for stimulated cardiomyocyte cycling We tested whether rNRG1 therapy could stimulate the cycling of cardiomyocytes from patients with heart disease. To accomplish this, we modified an organotypic cell culture system for primary human myocardium (39) . A parallel sheet-like arrangement of cardiomyocytes, sarcomeric striations (Fig. 7A) , and gap junctions ( ; ErbB4 F/F (test) mice. rNRG1 or BSA was administered from P0 until P12. ErbB4 inactivation was induced with tamoxifen administration from days P1 to P3, which caused a significant down-regulation of ErbB4 mRNA levels (A). Representative example of a cardiomyocyte in M phase with orthogonal reconstructions along the XZ and YZ axes (shown by staining of heart sections with an antibody against H3P, B). Quantification of these sections showed that rNRG1 increased cardiomyocyte cell cycle activity in ErbB4 F/WT but not in ErbB4 F/F mice (C). Statistical test by Student's t test (A) and ANOVA followed by Bonferroni's multiple comparison test (C). *P < 0.05, ****P < 0.0001. Scale bar, 50 mm. Functional annotation clustering of differentially expressed genes shows significant differences in the expression of components of multiple biological pathways by rNRG1. GO, Gene Ontology, a major bioinformatics initiative to unify the representation of gene and gene product attributes enabling functional interpretation of experimental data through enrichment analysis. P values were generated by DAVID bioinformatics tools. Fisher's exact test was adopted to measure gene enrichment in annotation terms.
is a suitable platform for studies of cardiomyocyte cell cycle stimulation. The 3D culture enabled us to test molecular manipulations that mimic therapeutic interventions and to determine the effect on cardiomyocyte proliferation in situ without disrupting the native myocardial tissue architecture. Myocardial samples were collected at the time of surgery and maintained for 72 hours with either rNRG1 at 100 ng/ml, the same concentration that stimulated the cycling of cultured cardiomyocytes (22, 29, 30) , or fetal calf serum (FCS; 1 or 20%). Tissue samples were subsequently sectioned and stained with antibodies to a-actinin and H3P (Fig. 7C) , and the number of mitotic cardiomyocytes was quantified manually using fluorescence microscopy ( Fig. 7D and table S4 ). Compared with controls (1% FCS; n = 8 hearts studied, all <6 months old), rNRG1 induced an increase in the M-phase cardiomyocyte population in the myocardium by 13-to 31-fold from patients 2 to 5 months of age (n = 8 hearts studied; Fig. 7D and table S4 ). In samples from 14 patients ≥6 months of age [age range, 6 months to 66 years ( Fig. 7D and table S4) ], no M-phase cardiomyocytes were detected. These results indicate that infants with heart disease who are <6 months of age have cardiomyocytes that can be induced with rNRG1 to reenter the cell cycle.
Infants with heart disease show the capacity for stimulated cardiomyocyte proliferation We used a nongenetic labeling technique with the fluorescent dye carboxyfluorescein succinimidyl ester (CFSE; fig. S10 ) to identify proliferating human cardiomyocytes. In the CFSE assay, fluorescein-protein adducts are retained by cells and diluted by half with every cell division. Using our organotypic culture system, we labeled the myocardium with CFSE and identified cardiomyocytes that had divided with the use of flow cytometry and a forward and side scatter gating strategy to enrich for large cells (cardiomyocytes; Fig. 8A , left panel) and to exclude doublets and cell aggregates (Fig. 8A , middle panel) (13) ; dead cells were excluded with 7-aminoactinomycin D (7-AAD) dye (Fig. 8A, right  panel) . CFSE populations were quantified in the FL1 channel and revealed two distinct populations (CFSE lo and CFSE hi ). Figure 8B shows representative data from a 3-month-old infant who exhibited a CFSE lo population of 4.1%. The CFSE lo population represents cardiomyocytes that have undergone several cell divisions, whereas the CFSE hi population represents quiescent cardiomyocytes. A CFSE hi population was found in every heart (fig. S11). We isolated the CFSE lo population for lineage reanalysis and stained it with an isotype antibody to examine the nonspecific binding of the cardiac troponin T (cTnT) antibody (Fig. 8C, left panel) ; staining with an antibody against cTnT showed that 94.7% of this cell population was cardiomyocytes (Fig. 8C, right panel) . These cardiomyocytes had similar forward and side scatter characteristics (Fig. 8D ) compared to the original forward and side scatter gate settings (Fig. 8A, left panel) . These experiments demonstrate that the CFSE lo cells in Fig. 8B are indeed cardiomyocytes. To further characterize the CFSE lo population, we bulk-sorted the cells, isolated RNA, and performed reverse transcription polymerase chain reaction (RT-PCR) analysis to examine the expression of selected marker genes. CFSE lo cardiomyocytes expressed the heart-specific markers cTnT and b-myosin heavy chain (b-MHC) but not the stem cell marker c-Kit, suggesting that this population contained mature differentiated cardiomyocytes and no dividing stem cells (40) (Fig. 8E) . Furthermore, cell cycle-related genes were expressed in the CFSE lo but not in the CFSE hi population (Fig. 8F) . After this extensive validation of the CFSE assay, we examined by flow cytometry the CFSE lo population in infant patients with heart disease (n = 16). Quantification showed that the CFSE lo population was 5.8 ± 1.7% (n = 4) at 2 months, 5 ± 1.4% (n = 3) at 3 months, and 1.2 ± 0.9% (n = 4) at 6 months of age (Fig. 8G and fig.  S11 ). CFSE lo populations were not detectable in patients over 6 months of age, indicating that patient age is an important determinant in the proliferative response to rNRG1 (Fig. 8G) .
Last, we examined the possibility that rNRG1 stimulation increased the proportion of cardiomyocytes with higher DNA contents, which may arise from DNA synthesis without subsequent nuclear division (endocycling) or nuclear division without subsequent cell division (endomitosis). Addition of rNRG1 did not change the proportion of mononucleated cardiomyocytes (Fig. 8H) or ploidy in the mononucleated portion (Fig. 8I) . This supports the conclusion that rNRG1 stimulates cardiomyocyte division in intact infant human myocardium. 
DISCUSSION
The findings herein advance a strategy for inducing myocardial repair in pediatric patients. Myocardial regeneration experiments in neonatal mice were not feasible until the recent introduction of techniques for inducing myocardial injury (15, 17, 41) . LAD ligation (16, 17) and amputation injury (15, 42) in neonatal mice were reported to lead to scarless repair, although these results are controversial (43, 44) . Here, we verify that cryoinjury is a technically feasible method that produces scar formation and dysfunction, which is in line with the scar formation and delayed repair process observed in zebrafish (31) (32) (33) and neonatal mice (35, 36) after cryoinjury. We also show that cryoinjury in neonatal mice is a useful model for human infants with heart disease because it recapitulates the scar formation, dysfunction, and decrease in cardiomyocyte cell cycle activity frequently seen in young patients with heart disease. The observed decrease in cardiomyocyte proliferation after cryoinjury contrasts with the reported increase in cardiomyocyte cycling after LAD ligation (16) and amputation (15) , possibly because of technical differences in the scoring of cardiomyocyte cell cycle events (45) . Our results suggest that a population of proliferationcompetent cardiomyocytes exists in young mammals and is inhibited or depleted by heart disease. Administration of rNRG1 rescued this inhibition to near-normal levels (about twofold increase) and stimulated the generation of new heart muscle in neonatal mice after cryoinjury and in organotypic cultures of myocardium from infants with heart disease (2 to 5 months of age).
Our model of the mechanisms activated by early administration of rNRG1 in mice involves myocardial protection and regeneration. What are their relative contributions to the overall reparative process? Comparison of the extent of myocardial death between BSA-and rNRG1-treated mice in the early administration group at 1 dpi showed a difference of~14%, corresponding to~136,000 cardiomyocytes. On the basis of the H3P analyses, 0.04% of these 136,000 protected cardiomyocytes actively cycle, resulting in~25,000 new cardiomyocytes over a 34-day period (Supplementary Results). On the other hand, direct quantification of cardiomyocyte nuclear density at 34 dpi revealed 3.1 × 10 4 and 3.8 ×10 4 cardiomyocytes/ mm 3 for BSA-and rNRG1-treated animals, respectively, corresponding to a difference of 7,000 cardiomyocytes/ mm 3 . Subtracting the number of cardiomyocytes contributed by protection, this corresponds to an additional~224,000 new cardiomyocytes in rNRG1-treated animals in the early administration regimen. From these data, we calculated that the new cardiomyocyte population generated by stimulated proliferation of uninjured cardiomyocytes accounts for 89% [(199,000/224,000) × 100] and the new cardiomyocyte population generated by proliferation of protected cardiomyocytes accounts for 11% [(25,000/224,000) × 100] of the total new cardiomyocyte population. We calculated the relative contributions of rNRG1-induced cardiomyocyte protection as 38% {[136,000/ (334,000 + 25,000)] × 100}, with the remaining 62% resulting from rNRG1-stimulated cardiomyocyte proliferation (Supplementary Results). In addition to the increase in the number of cardiomyocytes, rNRG1 might activate other beneficial mechanisms, as suggested by the transient improvement of myocardial function after late administration. The broad range of genes that displayed changes in expression levels after rNRG1 administration (Fig. 5) is consistent with the function of the NRG1 gene product in sustaining the cardiac gene regulatory network during development (19) . The rNRG1-regulated genes might hold clues for a deeper understanding of the biological mechanism(s) activated with rNRG1 administration.
The timing of the rNRG1 therapeutic period identified in neonatal mice after cryoinjury was different from that in human infants. In mice, this period ended within the first 5 days of life and is similar to the reported transient period of scarless repair after LAD ligation (16, 17) . In humans, this therapeutic window ended at about 6 months of age (Fig.  7D) , which is significantly shorter than would have been predicted from our results in humans without heart disease (10). The timing of the rNRG1 therapeutic window in humans leads to two conclusions: (i) administration of rNRG1 in human infants <6 months of age may induce cardiomyocyte regeneration, and (ii) because our mechanistic model involves cardiomyocyte protection, rNRG1 could be administered in infants with congenital heart disease before surgical repair, which is feasible because most of these surgeries are scheduled electively.
It is intriguing to note that human cardiomyocyte cell cycle reentry was not stimulated by rNRG1 in patients older than 6 months (Fig. 7D, Fig.  8G ). We demonstrated previously that rNRG1 stimulates cardiomyocyte division in young adult mice (22) . Setting aside potential species differences, how could this apparent discrepancy be reconciled? As shown in Fig. 6C , premature cessation of cardiomyocyte cycling occurred in the presence of heart disease, indicating that heart disease in infants drives proliferationcompetent cardiomyocytes out of the cell cycle and into a permanently quiescent phenotype. In contrast, the young adult mice characterized in (22) were free from heart disease until 8 weeks of life. In other words, these mice were not exposed to signals that drive cardiomyocytes prematurely into a permanently quiescent phenotype. It is likely that, as a result, cardiomyocytes with proliferative potential remain present into adulthood and could be stimulated by rNRG1.
Because induction of cardiomyocyte proliferation with rNRG1 appears to be a conserved mechanism in neonatal mice and in myocardium from human infants, targeting the growth factor could represent a therapeutic strategy for pediatric patients with heart disease. rNRG1 therapy might have risks associated with its proliferative effects in other organs. However, clinical studies that investigate the safety and efficacy of rNRG1 as a cardiac therapeutic in adult patients with heart failure have thus far provided no evidence of uncontrolled growth effects (27, 28) . Furthermore, the systemic administration of other recombinant growth factors (for example, insulin, granulocyte-macrophage colony-stimulating factor, erythropoetin, thrombopoetin, and insulin-like growth factor 1) that modify the activity of well-defined signaling pathways is a successful therapeutic paradigm and has a good track record for safety in pediatric patients.
MATERIALS AND METHODS
Study design
For the mouse experiments, the study design, including the number of animals to be included and the type and time points of analyses, was predefined by the investigators. Neonatal mouse cryoinjury was performed by B.D.P., and future assignment to rNRG1 and BSA administration was independently performed by B.G. cMRI was performed and analyzed independently by D.G.B. Investigators were blinded with the use of coded samples. Study objects (neonatal mice and human heart samples) were not excluded on the basis of results being outliers. The number of biological and technical replicates is provided in table S9.
Cryoinjury
Mouse experiments were approved by Boston Children's Hospital and Institute of Molecular Biotechnology. ICR mice were used. Pups born after 5:00 p.m. were considered to be P0 the following day and subjected to cryoablation the next day (P1). Pups received a subcutaneous injection of 0.1% bupivacaine, were placed inside a sleeve, and were put in an ice-water bath until they were nonresponsive to the paw reflex. Ventrolateral thoracotomy was performed between the fourth and fifth ribs, the pericardium was removed, and the heart was exposed. A 1.5-mm diameter vanadium probe was equilibrated in liquid nitrogen for 20 min and applied to the LV epicardium for 2 s. Sham injury consisted of opening the chest and removing the pericardium. The chest was closed with 6-0 Prolene sutures, and the skin was sealed with Webglue (Webster Veterinary) or 8-0 Prolene sutures. Pups recovered under a heating lamp, were placed on a warming blanket until they became responsive, were rubbed with bedding, and were returned to their mothers.
Visualization of injury by TTC
Freshly excised mouse hearts were washed in ice-cold 50 mM potassium chloride in phosphate-buffered saline (PBS), immediately placed in 1% TTC (w/v; in phosphate buffer, pH 7.4) at 37°C for 20 min, and then fixed in 10% phosphate-buffered formaldehyde overnight. Photomicrographs were taken using a Nikon SMZ1000 stereomicroscope at ×0.8, ×2, or ×3 magnification and an Olympus DP70 charge-coupled device camera.
Characterization of scar structure and function
We defined a transmural scar as the presence of transmural blue collagen on any of 6 to 12 AFOG-stained sections per heart. We measured the radial thickness of nontransmural scars and remote LV myocardium in diastole and systole on cMRI images using ImageJ and calculated relative systolic thickening as percent systolic change = (length in systole − length in diastole)/length in systole. Quantification of myocardial function in vivo by echocardiography and cMRI We performed transthoracic echocardiography under anesthesia with a Vevo 2100 device (VisualSonics). cMRI was performed under isoflurane anesthesia with a 9.4-T small-animal MRI scanner (Bruker BioSpin MRI). Details of imaging are provided in Supplementary materials and methods.
RNAseq sample preparation and data analysis Total RNA was extracted using the RNeasy Micro kit (Qiagen). Complementary DNA (cDNA) libraries were prepared using the TruSeq Stranded mRNA kit (Illumina). Sequencing was performed on NextSeq 500 instruments (single-strand, single-end indexed, 75 base pairs per read) at a depth of 35 × 10 6 per sample. Single reads were mapped to the mouse genome (m10) using STAR in a strand-specific manner. Cufflinks was used to determine the FPKM (fragments per kilobase of exon per million fragments mapped) levels for each gene from the STAR alignment and was used as input for Cuffdiff. All treatment groups were normalized to sham. Differential gene expression was calculated using Cuffdiff. Read counts were normalized between all samples. Genes with significant change of expression were defined by an adjusted P value <0.05 (Maverix Biomics). Functional clustering was performed with DAVID online software. Supplementary Materials and Methods provide additional information.
Human myocardial samples
Discarded and de-identified human myocardial samples were collected from patients undergoing heart surgery [Institutional Review Board (IRB) protocol #Z06-10-0489]. Clinical information was retrieved through an honest broker (IRB-P00000126). Normal human heart samples, including one fetal heart, were provided by the Sydney Heart Bank at The University of Sydney (Project No: 2012/2814). When known, patients with a 22q11 microdeletion were excluded. For detailed information, please refer to tables S2 to S5.
Human cardiomyocyte dissociation
Myocardial tissue was washed and resuspended in cold isolation buffer [130 mM NaCl, 5 mM potassium chloride, 1.2 mM monopotassium phosphate, 6 mM Hepes, 5 mM sodium bicarbonate, 1 mM magnesium chloride, and 5 mM glucose (pH 7.4)]. Isolation buffer was supplemented with 0.36 mM calcium chloride for enzyme activity. Cardiac tissue was incubated for 15 to 20 min in isolation buffer supplemented with collagenase IV (Sigma). After each incubation step, the supernatants were transferred into a tube and centrifuged at 600 rpm for 4 min. Cell pellets were resuspended in ice-cold isolation buffer. Several rounds of digestion were performed until the tissue was fully digested.
Laser scanning cytometry Myocardial cell preparations were prepared as described above, and laser scanning cytometric analysis for nucleation and ploidy was performed as previously described (10) .
CFSE assay CFSE is a fluorescein-derived intracellular fluorescent label that is divided between daughter cells upon cell division. Human myocardial samples were washed twice in warm PBS, incubated in PBS/2% FBS containing 0.5 mM CFSE (Molecular Probes, C1157) at 37°C for 30 min, and washed with 10× volume of ice-cold PBS/2% FBS. Samples were washed once with warm Dulbecco's modified Eagle's medium (DMEM) and incubated in supplemented DMEM for 72 hours. Cardiomyocytes were then isolated as described in "Human cardiomyocyte dissociation" section and analyzed on a FACSAria II (BD Bioscience) in the FL-1 channel. Viable populations were distinguished by 7-AAD. For lineage reanalysis of the CFSE lo population, cells were gated according to CFSEloaded but non-rNRG1-stimulated controls, and 10,000 cells were bulksorted into PBS/5% FCS from two patient samples. Cells were fixed in 4% paraformaldehyde (PFA) for 15 min, washed, stained with either primary antibodies to cTnT (Neomarkers) or an isotype control (immunoglobulin G1), and conjugated to FITC fluorophore. Cells were analyzed on a FACSAria II.
Flow cytometry and FACS Dissociated cardiomyocytes were prepared as previously described (10), washed, and pelleted for antibody staining. For cell cycle analysis, sarcomeric a-actinin (Sigma) antibody was conjugated to a FITC secondary antibody and H3P (Upstate) antibody was conjugated to a Pacific Blue secondary antibody (both from Invitrogen, Molecular Probes monoclonal antibody conjugation kits). Cells were fixed in 4% PFA and washed twice with PBS/5% FCS. Cells were stained in PBS/5% FCS and antibody cocktail for 1 hour at 4°C, washed twice, and resuspended in PBS/5% FCS. Samples were acquired on a FACSAria Cell Sorter (BD Biosciences), and data were analyzed with FlowJo software.
Quantitative RT-PCR Cardiomyocytes were isolated and sorted with a FACSAria II (100 mm nozzle) into TRIzol buffer and were frozen at −80°C. RNA extraction was performed with an RNeasy Micro Kit (Qiagen) according to the manufacturer's instructions, including on-column DNase I digestion. cDNA was synthesized from 200 ng of total RNA. Eluted RNA samples were reverse-transcribed using SuperScript II and random hexamers (Invitrogen). PCR was performed using iQ5 real-time PCR thermal cycler or Bio-Rad CFX384 Touch thermal cycler and iQ SYBR Green Supermix (Bio-Rad) or iTaq Universal SYBR Green Supermix. The normalized values of each biological replicate were averaged before the calculation of fold change in expression levels. The primer sequences are provided in tables S10 and S11.
Statistical analyses
Numerical results are presented as means ± SEM. Statistical testing was performed with Student's t test, Fisher's exact test, and ANOVA followed by Bonferroni post hoc testing. Statistical significance was achieved with a two-sided P value ≤0.05. Statistical analyses were performed with GraphPad Prism, version 6.
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